VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed incurable relapsed or refractory solid tumor or non-Hodgkin's lymphoma that has been treated on MSKCC-01131 * Must have completed participation in protocol MSKCC-01131 through visit 16 and have shown evidence of stable disease or complete or partial remission of tumor burden and no evidence of symptomatic deterioration * No adverse event or toxicity which resulted in discontinuation of participation in protocol MSKCC-01131 * If a patient experienced dose-limiting toxicity, then the patient must have demonstrated the ability to tolerate the same dose or a lower dose prior to entry in this study * No known or suspected squamous cell carcinoma of the lung * No prior or concurrent new neurological symptoms or CNS (brain or leptomeningeal) metastases during protocol MSKCC-01131 PATIENT CHARACTERISTICS: Age * 25 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * WBC at least 3,500/mm3 * Absolute neutrophil count at least 1,500/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 9.0 g/dL * No severe or uncontrolled hematologic condition Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST and ALT no greater than 2 times ULN * Alkaline phosphatase no greater than 2 times ULN * PT, PTT, and INR normal Renal * Creatinine no greater than ULN * No 1+ or greater proteinuria * No severe or uncontrolled renal condition Cardiovascular * No severe or uncontrolled cardiovascular condition Pulmonary * No severe or uncontrolled pulmonary condition Other * No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap) * No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal condition * No severe or uncontrolled psychiatric condition or adverse social circumstance that would preclude study * No other condition that would preclude study * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective double-barrier contraception during and for at least 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF) * No other concurrent immunotherapy Chemotherapy * No concurrent standard chemotherapy Endocrine therapy * No concurrent adrenal corticosteroids except low doses as replacement therapy in patients who have previously received suppressive doses or for adrenal insufficiency * No concurrent systemic hormonal contraceptive agents Radiotherapy * No concurrent radiotherapy Surgery * Not specified Other * At least 30 days since prior investigational therapy other than VEGF Trap * No concurrent standard or other investigational anticancer agents * No concurrent herbal supplements ("nutraceuticals") * No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, aspirin, or other nonsteroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2 (COX-2) inhibitors for analgesia * No concurrent COX-2 inhibitors for tumor treatment or prophylaxis